Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database

Drug Safety

Volumn 38, Issue 11, 2015, Pages 1103-1113

  Watkins, Paul B ^a   Lewis, James H ^b   Kaplowitz, Neil ^c   Alpers, David H ^d   Blais, Jaime D ^e   Smotzer, Dan M ^e   Krasa, Holly ^e   Ouyang, John ^e   Torres, Vicente E ^f   Czerwiec, Frank S ^e   Zimmer, Christopher A ^e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; PLACEBO; PREDNISONE; TOLVAPTAN; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; DATA BASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HUMAN; HYPONATREMIA; JAUNDICE; KIDNEY POLYCYSTIC DISEASE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MIDDLE AGED; MORNING DOSAGE; NAUSEA; NON INFECTIOUS HEPATITIS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; CASE REPORT; CHEMICAL AND DRUG INDUCED LIVER INJURY; FACTUAL DATABASE; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; STATISTICS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; CHEMICAL AND DRUG INDUCED LIVER INJURY; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC;

EID: 84945491715     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0327-3     Document Type: Article

References (25)

1. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477–85.
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287–301.
3. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10):556–66.
4. United States Renal Data System. 2014 annual data report: an overview of the epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014.
5. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63(6):1983–94.
6. Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11(7):1179–87.
7. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323–6.
8. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10(4):363–4.
9. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.
10. Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243–52.
11. United States Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed 11 Feb 2015.
12. Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests? Clin Pharmacol Ther. 2009;85(3):331–4.
13. Regev A, Seeff L, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl 1):S47–56.
14. Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117–26.
15. Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55–68.
16. Augmentin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006.
17. Teschke R, Frenzel C. Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today? Ann Hepatol. 2013–2014;13(1):121–6.
18. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667–73.
19. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711–4.
20. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186–95.
21. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastoenterol Hepatol. 2015;13(1):155–64.
22. Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64–9.
23. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10(2):151–60.
24. Otsuka Pharmaceutical Development & Commercialization, Inc. Tolvaptan phase 3 efficacy and safety study in ADPKD (TEMPO3/4) [ClinicalTrials.gov identifier NCT00428948]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 8 Jul 2015.
25. Otsuka Pharmaceutical Development & Commercialization, Inc. Open-label tolvaptan study in subjects with ADPKD (TEMPO 4/4) [ClinicalTrials.gov identifier NCT01214421]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 8 Jul 2015.